The imperative to explore additional biomarkers is underscored by the current recommendation in national guidelines, which primarily includes KRAS, NRAS, BRAF, and MSI status for evaluating treatment response and predicting outcomes in CRC [85]. The gene discussed is BRAF; the disease is colorectal carcinoma.